DeciBio Consulting Launches Emmes SARS-CoV-2 Testing Database

LOS ANGELES--(BUSINESS WIRE)--#COVID19--DeciBio Consulting, a strategy consulting firm dedicated to the precision medicine space, has launched the Emmes SARS-CoV-2 Testing Database. This database serves as the latest addition to the market intelligence products already under DeciBio Consulting’s umbrella. Such products include the Emmes Infectious Disease Database, the Emmes Oncology Database, BioMAP (immuno-oncology biomarkers), Marketbooks, Dexter, and BioTrack, among others.


The DeciBio Emmes SARS-CoV-2 Testing Database provides data visualization tools and raw data covering coronavirus testing practices in approximately 400 labs in the United States. This data includes diagnostic and serology testing details at hospital, public health, and commercial reference labs, as well as send-out volumes.

DeciBio Consulting’s managing partner David Cavanaugh notes, “Adequate testing is one of the primary ways the country can overcome the pandemic. DeciBio’s SARS-CoV-2 Database aims to provide insights into current testing behavior and trends to measure how the testing industry is responding to the pandemic.”

Example preliminary results indicate that, although the supply of kits and the adoption of in-house testing continue to increase:

(1) Nearly half of labs have reported that kit availability fails to meet demand; consequently, one third of surveyed labs use multiple platforms. Testing at these labs account for a majority of total volumes for the database.

(2) Some labs have reported reduced operational hours affecting testing outputs.

(3) Serology test adoption is beginning to mature but lags behind diagnostic testing.

The SARS-CoV-2 Testing Database collects information on platforms and kits used, sample collection devices, co-testing behaviors, and more. Startups, industry-leading test manufacturers, and Fortune 500 Life Science companies alike are using this database to keep a finger on the pulse of the rapidly evolving SARS-CoV-2 testing environment and adapt accordingly.

The database and easy-to-navigate visualization suite are available on a subscription basis for clients in sales, development, strategic, investment analytics / market research, and operations roles. To learn more about the SARS-CoV-2 Testing Database or to schedule a demo, visit https://www.decibio.com/intelligence/emmes-databases/

About DeciBio

DeciBio Consulting is a strategy consulting firm focused on precision medicine. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, and corporate due diligence.

About Emmes Databases & DeciBio Analytics

The Emmes databases are managed and marketed through DeciBio Consulting’s market intelligence subsidiary, DeciBio Analytics. Through the Emmes databases and other products, DeciBio Analytics aggregates public and proprietary data to build proprietary software and data visualization products.


Contacts

David Cavanaugh
emmesdata@decibio.com
310-451-4510